{"changeSha256":"2ffa70397c4620ac5b1d9feb32b86ea3703d3cefc99d84b39aee4bb692a83a7d","changedAt":"2026-11-14","changedFields":[{"after":"In clinical trials; not FDA-approved","before":"Investigational","field":"Status"},{"after":"An experimental glucagon and GLP-1 receptor dual agonist from Boehringer Ingelheim, studied in obesity and fatty liver disease. It is not FDA-approved.","before":"A glucagon/GLP-1 receptor agonist candidate. This profile cites a ClinicalTrials.gov study record that was active, not recruiting.","field":"Profile summary"},{"after":"Published randomized trials, including the Phase 3 SYNCHRONIZE-1 trial, report weight loss and liver-fat reductions. A completed cardiovascular safety trial has no results in the cited sources. FDA has warned companies selling unapproved survodutide with false research-use labels.","before":"ClinicalTrials.gov lists a Boehringer Ingelheim study as active, not recruiting, updated July 22, 2026.","field":"Evidence note"},{"after":"ctg-nct05202353-v50, fda-unapproved-glp1-concerns-2026-r2, journal-pmid-38330987, journal-pmid-38847460, journal-pmid-42253238, journal-pmid-42252333, ctg-observation-nct06077864-2026-08-11-60e24ca2b385, ctg-observation-nct06632444-2026-08-10-1ea3a43e551b, ctg-observation-nct07754461-2026-08-10-d71d6065261a","before":"ctg-nct05202353-v50","field":"Cited source records"},{"after":"Boehringer Ingelheim [sources: ctg-nct05202353-v50]; U.S. Food and Drug Administration [sources: fda-unapproved-glp1-concerns-2026-r2]","before":"Boehringer Ingelheim [sources: ctg-nct05202353-v50]","field":"Named organizations"},{"after":"name: ctg-nct05202353-v50; aliases: ctg-nct05202353-v50; category: ctg-nct05202353-v50; status: ctg-nct05202353-v50, ctg-observation-nct07754461-2026-08-10-d71d6065261a, fda-unapproved-glp1-concerns-2026-r2; summary: ctg-nct05202353-v50, journal-pmid-38330987, journal-pmid-42253238, fda-unapproved-glp1-concerns-2026-r2; evidenceNote: journal-pmid-42253238, journal-pmid-42252333, ctg-observation-nct06077864-2026-08-11-60e24ca2b385, fda-unapproved-glp1-concerns-2026-r2","before":"name: ctg-nct05202353-v50; aliases: ctg-nct05202353-v50; category: ctg-nct05202353-v50; status: ctg-nct05202353-v50; summary: ctg-nct05202353-v50; evidenceNote: ctg-nct05202353-v50","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/survodutide/versions/3/","version":3},"id":"profile:survodutide:v3","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-status-changed","notice":"We added a plain-language reader guide with cited answers, published trial results from our human evidence review, current ClinicalTrials.gov records, and FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026), which names survodutide among unapproved drugs sold with false research-use labels.","peptideSlugs":["survodutide"],"previousChangeEvent":{"path":"/corrections/v1/profiles/survodutide/v2.json","sha256":"e44677226e64a6dc0b801603408c345f8f6dc9b2d6c9571a5abff5c137afb095"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/survodutide/versions/2/","version":2},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"fda-unapproved-glp1-concerns-2026-r2","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","verifiedAt":"2026-11-14"},{"id":"journal-pmid-42253238","name":"The New England Journal of Medicine","sourceClass":"A","title":"Survodutide Once Weekly for the Treatment of Adults with Obesity (SYNCHRONIZE-1, 2026) · PMID 42253238","url":"https://doi.org/10.1056/NEJMoa2600751","verifiedAt":"2026-11-14"},{"id":"ctg-observation-nct06077864-2026-08-11-60e24ca2b385","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT06077864 · retained source version 2026-08-11:60e24ca2b3858aa7bfd06f0e1cac79051207229d8181cdbe15a0399bddf60984","url":"https://clinicaltrials.gov/study/NCT06077864","verifiedAt":"2026-08-14"}],"subject":{"slug":"survodutide","type":"profile"}}
